CONCORD -
With a firmware update, users will be able to update their iLet to integrate with Dexcom G7 without any additional cost for new hardware.
Beta Bionics' flagship product, the iLet Bionic Pancreas, is an autonomous insulin delivery system that streamlines diabetes management and reduces the burden on patients and physicians. The only input required to get started is the user's weight - the iLet does the rest. Healthcare providers no longer need to determine complex settings including correction factors, insulin-to-carb ratios or pre-set basal rates. When iLet users 'GO BIONIC' with their diabetes management, there's no carb counting or calculating insulin corrections throughout the day - the iLet determines 100% of the insulin doses.
With the Dexcom G7 integration, users can experience the freedom and benefits of the iLet Bionic Pancreas with the fastest(++) and most accurate CGM1,2 available. Dexcom G7 features an all-in-one sensor and transmitter, no fingersticks from day 1(+) and only a 30-minute warmup(++) time when starting a new sensor. Dexcom CGM also enables you to share your numbers with up to 10 people with the Dexcom Follow app, allowing users to stay connected with their loved ones and care teams. This iLet Bionic Pancreas firmware update will allow users to select Dexcom G7 or Dexcom G6 CGMs, or switch back and forth, depending on their supplies.
'Our goal is to give our patients choice with their CGM technology and to be able to update quickly and easily without new hardware or additional costs,' explained
'Dexcom G7 was designed with connectivity in mind and this latest integration with Beta Bionics is a testament to that,' said
To upgrade, existing iLet Bionic Pancreas users can download or update the iLet app from the
About Beta Bionics
Beta Bionics is a medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas in both the single hormone and bi-hormonal configurations. The iLet Bionic Pancreas platform is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body's natural ability to maintain tight glycemic control, relieving some of the burden of living with diabetes.
Beta Bionics is a for-profit, public benefit corporation and
Contact:
Email: ir@betabionics.com
(C) 2023 Electronic News Publishing, source